Wolfgang Miesbach: Excellent 4-Year Data of Etranacogene Dezaparvovec in Haemophilia B
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:
”Excellent 4-Year Data of Etranacogene Dezaparvovec in Haemophilia B: The Subgroup (N=33) With No Neutralizing Anti-AAV Antibodies (NAb-Negative):
- 100% expressed endogenous FIX at therapeutic levels (mean 39.0 IU/dL)
- 100% remained prophylaxis-free over 4 years—zero returned to prophylaxis
- Exogenous FIX consumption decreased by 99%
- 85% reduction in bleeds (all, spontaneous, joint)
- Safety: Treatment-related AEs only first 3 months; transient ALT elevations 18%, all manageable
This enables direct comparison to other haemophilia B gene therapies where only NAb-negative patients were enrolled.
HOPE-B’s Inclusive Design
HOPE-B is the first—and currently only—haemophilia B gene therapy trial to include patients with pre-existing AAV neutralizing antibodies for treatment with etranacogene dezaparvovec.
Very recently, the NEJM paper presented 5-year data of the full cohort (NAb-negative and NAb-positive; N=54).
Congratulations to Priyanka Raheja and co-authors!”
Read the full article here.
Article: Etranacogene dezaparvovec in participants with hemophilia B and without adeno-associated virus serotype 5 neutralizing antibodies: A 4-year subgroup analysis (HOPE-B)
Authors: Priyanka Raheja, Niamh O’Connell, Peter Verhamme, Peter Kampmann, Richard S. Lemons, Fei Wang, Sean Gill, Paul E. Monahan, Sandra Le Quellec, Frank W. G. Leebeek
Stay updated on all scientific advances with Hemostasis Today.
-
Feb 20, 2026, 17:35Wolfgang Miesbach: Plasma FIX Is Only Part of the Story In Haemophilia B
-
Feb 20, 2026, 17:27Sheharyar Raza: Examining Guideline Discordance in Evidence-Based Apheresis Recommendations
-
Feb 20, 2026, 17:23Barbara Mora: Newly Discovered EPO Gene Intronic Variant as a Cause of Congenital Erythrocytosis
-
Feb 20, 2026, 16:48Miguel Brito: Newborn Screening and Challenges in Follow-Up Care for Sickle Cell Disease in Angola
-
Feb 20, 2026, 16:41Uche Kennedy: Hemophilia Care Needs Systems Reform, Not Short-Term Fixes
-
Feb 20, 2026, 16:33Sonal Sonu: Real Clinical Maturity is Knowing When to Stop
-
Feb 20, 2026, 16:27Clear Recommendations for Daily Management and Family Support in Hemophilia A – WFH
-
Feb 20, 2026, 15:56Alan Nurden: Highlighting the Role of Activated Platelets in Heart and Kidney Complications of Diabetes
-
Feb 20, 2026, 15:51Domenico Girelli: Continuing Commitment to Rare Disease Research